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Abstract
These European Society for Clinical Microbiology and Infectious Diseases and European Confederation of Medical Mycology Joint Clinical Guidelines focus on the diagnosis
and management of mucormycosis. Only a few of the numerous recommendations can be summarized here. To diagnose mucormycosis, direct microscopy preferably using
optical brighteners, histopathology and culture are strongly recommended. Pathogen identiﬁcation to species level by molecular methods and susceptibility testing are
strongly recommended to establish epidemiological knowledge. The recommendation for guiding treatment based on MICs is supported only marginally. Imaging is strongly
recommended to determine the extent of disease. To differentiate mucormycosis from aspergillosis in haematological malignancy and stem cell transplantation recipients,
identiﬁcation of the reverse halo sign on computed tomography is advised with moderate strength. For adults and children we strongly recommend surgical debridement in
addition to immediate ﬁrst-line antifungal treatment with liposomal or lipid-complex amphotericin B with a minimum dose of 5 mg/kg/day. Amphotericin B deoxycholate is
better avoided because of severe adverse effects. For salvage treatment we strongly recommend posaconazole 4 9 200 mg/day. Reversal of predisposing conditions is
strongly recommended, i.e. using granulocyte colony-stimulating factor in haematological patients with ongoing neutropenia, controlling hyperglycaemia and ketoacidosis in
diabetic patients, and limiting glucocorticosteroids to the minimum dose required.We recommend against using deferasirox in haematological patients outside clinical trials,
and marginally support a recommendation for deferasirox in diabetic patients. Hyperbaric oxygen is supported with marginal strength only. Finally, we strongly recommend
continuing treatment until complete response demonstrated on imaging and permanent reversal of predisposing factors.
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Introduction
Mucormycosis is a very aggressive invasive fungal disease [1,2].
It is a fungal emergency that affects a variety of patient groups
[3]. The disease, previously termed zygomycosis [4], is caused
by mucoralean fungi, which have collectively also been called
Mucormycetes [5,6]. However, we prefer to use the name of
the order, i.e. Mucorales.
The genera causing the majority of mucormycoses are
Rhizopus, Mucor, Lichtheimia (previously classiﬁed as Absidia),
Cunninghamella, Rhizomucor, Apophysomyces and Saksenaea [7].
Granulocytopenia, immunosuppression, diabetes and penetrat-
ing trauma are the most prevalent predisposing diseases
associated with mucormycosis [7]. Cavitary pulmonary disease
due to Rhizopus homothallicus has been described as a distinct
pattern in diabetic patients in India [8]. Besides patients with
these typical risk factors, mucormycosis has been reported in
otherwise healthy individuals in India and China, e.g. in the forms
of renal mucormycosis and chronic (sub-)cutaneous infections
due to Mucor irregularis (Rhizomucor variabilis) [8–16]. Recently,
the different clinical manifestations have been reviewed [17].
Arnold Paltauf reported the ﬁrst histologically proven case
of Mycosis mucorina at the University of Graz, Austria in 1885
[18]. Though the disease has been known for a long time, the
epidemiology is not well deﬁned. In a study from France
mucormycosis had increasingly been diagnosed over the past
years, culminating in a general population incidence of 1.2 per
million/year [19]. Two further studies from Spain and Califor-
nia report incidences between 0.4 and 1.7 cases per million
population/year [20,21]. In patients with haematological malig-
nancy mucormycosis was less common than invasive aspergil-
losis, but mucormycosis independently predicted death in
these patients [22,23]. Lymphocytopenia has recently been
identiﬁed as independently predicting death in this setting [24].
Mortality rates in patients with mucormycosis remain high and
in recent reports they ranged from 24% to 49% [7,19,25,26].
Guidance for diagnosis and treatment of mucormycosis is
needed, because in rare diseases it is difﬁcult to execute
comparative clinical trials and to accumulate substantial
personal experience. This is particularly true for a disease
that is likely to be underdiagnosed and in which individual
prognosis is driven by early treatment [2,27]. This guidance
document will provide help to improve management of
invasive mucormycosis.
Methods
An expert group (OAC, SAA, AC, ED, AHG, KL, FL, LP, GP
and AS) was set up by the European Society of Clinical
Microbiology and Infectious Diseases (ESCMID) Fungal Infec-
tion Study Group (EFISG) and the European Confederation
of Medical Mycology (ECMM) and searched the literature
using the search string ‘mucormycos* OR zygomycos* NOT
entomophthoramycos* NOT phycomycos*’. Documents and
views were shared by email, teleconferences and face-to-face
meetings during April 2012 to April 2013. Once a structured
ﬁrst consensus was reached the preliminary recommenda-
tions were presented to the whole group, i.e. the other
authors, discussed, developed further and ﬁnalized as a group
consensus. The methods to evaluate the quality of evidence
and to reach group consensus recommendations are
described in the context of the ESCMID clinical guidelines
on Candida infection [28]. For the present guideline we
applied the same system to diagnostic procedures. The
deﬁnition of the strength of recommendation is given in
Table 1. The quality of the published evidence is deﬁned in
Table 2(a). To increase transparency regarding the evaluation
of available evidence we added an index (Table 2b) to the
level II recommendations, where appropriate. Of note, the
evaluation of the strength of recommendation and of the
quality of evidence was performed in two separate evalua-
tions, so allowing for a recommendation strongly supporting
a procedure even if there is a lower level of evidence. If
ESCMID EFISG and ECMM marginally support a recommen-
TABLE 1. Deﬁnition of the strength of recommendation
Grade ESCMID EFISG and ECMM
A Strongly support a recommendation for use
B Moderately support a recommendation for use
C Marginally support a recommendation for use
D Support a recommendation against use
TABLE 2. Deﬁnition of the quality of evidence
Level ESCMID EFISG and ECMM
(a)
I Evidence from at least one properly designed randomized, controlled
trial
II Evidence from at least one well-designed clinical trial, without
randomization; from cohort or case–control analytic studies
(preferably from more than one centre); from multiple time series;
or from dramatic results of uncontrolled experiments
III Evidence from opinions of respected authorities, based on clinical
experience, descriptive case studies, or reports of expert committees
Index ESCMID EFISG and ECMM
(b)
r Meta-analysis or systematic review of randomized controlled trials
t Transferred evidence, i.e. results from different patients’ cohorts,
or similar immune status situation
h Comparator group is a historical control
u Uncontrolled trial
a Abstract published at an international meeting
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dation for use, the respective intervention can be considered
optional [28].
Results
Recommendations on diagnostics in mucormycosis
Conventional microbiological methods. Direct microscopy of
clinical specimens, preferably using optical brighteners, allows
a rapid presumptive diagnosis of mucormycosis. Blankophor
and Calcoﬂuor bind to chitin and cellulose and ﬂuoresce in
ultraviolet light [29]. Hyphae of Mucorales have a variable
width (6–25 lm), are non-septate or pauci-septate and have an
irregular, ribbon-like appearance. The angle of branching is
variable and includes wide-angle (90°) bifurcations. Culture of
specimens is considered an essential investigation. Although
the sensitivity of culture is not optimal, it allows identiﬁcation
and susceptibility testing of the isolate in case of growth.
Histopathological examination of tissue specimens may allow
differentiation between hyphae of Aspergillus or morphologi-
cally related fungi, and hyphae of Mucorales, which is important
for treatment decisions. Mucormycosis is characterized by
prominent infarcts, angioinvasion and perineural invasion.
Evidence—The value of ﬂuorescent whiteners for computed
tomography (CT) -guided percutaneous lung biopsy specimens
was assessed in 61 patients with CT ﬁndings highly suggestive
of an invasive fungal infection [30]. Calcoﬂuor white staining
revealed fungal elements in 49 specimens (80%) and allowed
the differentiation between septate (n = 36) and non-septate
(n = 13) hyphae. The DNA of mucoralean fungi was detected
by PCR in all samples with non-septate hyphae. Calcoﬂuor
white analysis was considered false negative in 5% of specimens
[30]. In a patient with acute myelogenous leukaemia and
periodontal mucormycosis, intraoperative calcoﬂuor white
ﬂuorescence microscopy was used for a prompt diagnosis and
to guide the extent of surgical debridement. Maxillary biopsies
with intraoperative calcoﬂuor white analysis were used to rule
out persistent oral mucormycosis in this case [31].
Mucorales growwell on both non-selective and fungus-selec-
tive media and the growth tends to be rapid, i.e. covers the
entire plate in a few days. The recovery of Mucorales from
tissues may be problematic and negative cultures seem to be
correlated with aggressive processing of the specimens before
plating. Grinding of specimens should therefore be avoided [32].
The specimen is preferably incubated at 37°C [33–35].
Histopathological review of tissue samples from 20 patients
with rhinocerebral disease (n = 11), pulmonary disease
(n = 6), or a fungus ball (n = 3) revealed that the inﬂammatory
responses were predominantly neutrophilic (50%), pyogranul-
omatous (25%) or absent (20%). Invasive disease was charac-
terized by prominent infarcts (94%), angioinvasion (100%) and
prominent perineural invasion (90%) in biopsies that contained
nerve structures for evaluation. The presence of septa in the
hyphae was rare and hyphal branching angles varied from 45 to
90° [36]. Pulmonary mucormycosis in cancer patients (n = 20,
19 patients with haematological malignancy) is characterized by
angioinvasion (100%), haemorrhagic infarction (90%), coagula-
tive necrosis (85%) and intra-alveolar haemorrhage (85%).
Neutropenic patients had more extensive angioinvasion com-
pared with non-neutropenic patients [37]. In recent registries
of mucormycosis, histopathology led to the diagnosis in 63%
[26] and 66% [7] of cases. The diagnosis of 75 cases from an
Indian tertiary-care hospital was based on histopathology [38].
In a separate report three cases of mucormycosis were
diagnosed by immunohistochemistry using monoclonal anti-
bodies against somatic antigens of Rhizopus oryzae; two of
three had been misclassiﬁed as aspergillosis based on histopa-
thology alone [39].
Recommendations—Direct microscopy of clinical specimens
preferably using optical brighteners and culture is strongly
recommended for the diagnosis of mucormycosis. Histopa-
thology may allow differentiation of mucormycosis from
aspergillosis—and other hyalohyphomycoses and phaeohyph-
omycoses—and is strongly recommended. Notably, scrapings
do not reliably prove tissue invasion. Any microscopic
examination should evaluate morphology, width, branching
angle and septation. Direct microscopy is not useful for species
identiﬁcation, and immunohistochemistry is only marginally
supported for the diagnosis of mucormycosis due to the lack
of commercially available monoclonal antibodies and clinical
validation. For further recommendations refer to Table 3.
Detection of antigen and Mucorales-speciﬁc T cells. There are no
standardized assays available for the detection of Muco-
rales-speciﬁc antigens. The healthcare provider should have a
high level of suspicion that the patient has mucormycosis
rather than aspergillosis in patients with CT lesions that are
highly suggestive for invasive fungal disease, speciﬁcally if
Aspergillus galactomannan test results on serum and broncho-
alveolar lavage are negative [40]. Of note, 1,3-b-D-glucan is a
common component of the cell wall of a wide variety of fungi
but not of the Mucorales.
Evidence—At two centres with a high autopsy rate, muco-
rmycosis diagnosis was missed using a diagnostic strategy with
regular galactomannan testing of serum samples [41,42]. In a
study of breakthrough invasive mould infections in patients
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treated with caspofungin, two cases of mucormycoses
occurred among eight patients in whom galactomannan tests
remained negative [43].
In vitro analysis of culture supernatants of different species
causing mucormycosis (n = 8, four different species) revealed
a low antigen reactivity compared with other mould isolates,
presumably because of their low cell wall 1,3-b-D-glucan
concentrations [44]. Three patients with mucormycosis had
negative 1,3-b-D-glucan results in a multicentre evaluation of
the performance of the 1,3-b-D-glucan test for the diagnosis of
invasive fungal infections [45].
Mucorales-speciﬁc T cells were detected by an enzyme--
linked immunospot (ELISpot) assay in three haematological
patients developing invasive mucormycosis at diagnosis and
throughout the entire course of the invasive disease but not
for long after resolution of the infection. None of the 25
control patients without mucormycosis had Mucorales-speciﬁc
T cells [46].
Recommendations—The use of galactomannan detection is
moderately supported for the diagnosis of invasive muco-
rmycosis. In patients with a possible invasive fungal infection,
negative galactomannan test results in serum and BAL increase
the likelihood of invasive mucormycosis. 1,3-b-D-Glucan
testing is not recommended for the diagnosis of invasive
mucormycosis. For further recommendations refer to Table 3.
Molecular-based methods for direct detection. Evidence—An
in-house semi-nested PCR that targets the 18S ribosomal
DNA of Mucorales was evaluated on fresh tissue specimens in
two prospective studies [30,47]. In the ﬁrst study, PCR was
performed on 56 respiratory biopsy specimens obtained by
different procedures from immunocompromised patients
suspected of having a mould infection. The PCR was positive
in six samples with histopathological detection of Mucorales
hyphae but culture was positive in only two of these samples.
One false-positive result was obtained (2% of samples tested)
[47]. The second study was conducted on CT-guided percu-
taneous lung biopsy specimens obtained from 46 patients with
a haematological malignancy and 15 patients with solid-organ
transplantation. PCR detected mucoralean fungi in all speci-
mens with non-septate hyphae (n = 13, sensitivity 100%)
whereas culture remained negative in ﬁve cases [30].
The performance of the same semi-nested PCR as
described above was also evaluated on formalin-ﬁxed paraf-
ﬁn-embedded tissue specimens in two different studies
[48,49]. Mucorales PCR was positive in 22 of 27 tissue
specimens from patients with a haematological malignancy or a
haematopoietic stem cell transplant who were diagnosed with
mucormycosis [48] and in 14 of 23 specimens from patients
with the diagnosis of mucormycosis based on histopathology
[49]. The failure to amplify speciﬁc DNA might result from
fungal DNA concentrations below detection limits, a focal
infection with varying amounts of fungal elements within the
tissue or the destruction of DNA during formalin ﬁxation. In
four cases no human b-globin DNA could be detected by the
control PCR [49]. A recent exercise evaluated a pan-fungal
real-time PCR-based technique in formalin-ﬁxed paraf-
ﬁn-embedded tissue specimens [50]. In a total of 89 biopsies
from patients with invasive fungal diseases the average
TABLE 3. Recommendations on diagnosis of mucormycosis: laboratory diagnosis using conventional, serological and molecular
methods
Population Intention Method/Finding SoR QoE References Comment
Any To diagnose
mucormycosis
Direct microscopy
preferably using
optical brighteners
A IIu 30,31 Allows rapid presumptive diagnosis; non-septate or pauci-septate, irregular,
ribbon-like hyphae, angle of branching 45–90°, identiﬁcation to genus and
species level not possible, hyphal diameter in aspergillosis 2–3 lm, in
mucormycosis 6 to >16 μm
Any To diagnose Culture A IIIr 32,35 Avoid grinding, preferred temperature 37°C
Any To diagnose Histopathology A IIu 7,26,36–38 Features as in direct microscopy, does not allow for genus or species
differentiation; perineural invasion commonly seen, if nerves sampled
Any To diagnose Immunohistochemistry C IIu 39 No commercial assay available
Monoclonal antibodies commercially available
Any To diagnose Galactomannan in
blood or
bronchoalveolar lavage
B III 41
43
192
n = 2
n = 1
n = 2/8 missed mucormycoses: consider mucormycosis, if galactomannan
test negative, but radiology positive
Any To diagnose 1,3-b-D-glucan in blood D III 44,45 Not a reliable marker
Haematological
malignancy
To monitor
treatment
ELISPOT C IIu 46 No commercial assay available
Any To diagnose Molecular based tests on
fresh clinical material
B IIu 30,47,193,194 No commercial assay available; fresh material preferred over parafﬁn-
embedded
Any To diagnose Molecular based tests on
parafﬁn slides
B IIu 48,49, 51 No commercial assay available
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sensitivity of the PCR assay was 89% and Mucorales were
detected in 11% of biopsies, although the technique exhibited
some limitations to detect Rhizopus microsporus, Rhizopus
oryzae and Saksenaea vasiformis [50]. In an interlaboratory
evaluation of the reproducibility of an internal transcribed
spacer (ITS) PCR performed on formalin-ﬁxed parafﬁn-embed-
ded tissue specimens from experimentally infected mice,
positive results were obtained in 93% of samples with 30
slide cuts of 10 lm. Sensitivity decreased to 27% when tissue
quantity was reduced to one section. Interlaboratory repro-
ducibility was excellent [50,51]. Mucorales DNA was detected
in 40–60% of plasma samples with real-time PCR as early as
one day post-inoculation in a rabbit model of experimental
pulmonary mucormycosis [52].
Recommendations—Currently, in the absence of a standardized
test, the use of molecular methods on both fresh clinical
material and parafﬁn slides for the diagnosis of mucormycosis
is moderately supported. Fresh material is preferred over
parafﬁn-embedded tissue because formalin damages DNA. For
further recommendations refer to Table 3.
Genus and species identiﬁcation. There is no strong evidence that
identiﬁcation to the genus/species level may be important to
guide treatment. Identiﬁcation to the species level is of interest
for a better epidemiological knowledge of mucormycosis and
may be of value for outbreak investigation. Molecular techniques
are more reliable than phenotypic identiﬁcation of Mucorales in
culture to the species level. Sequencing of ITS is currently the
best molecular technique for species identiﬁcation. Carbon
assimilation proﬁles using the commercialized kits ID32C and
API 50 CH (bioMerieux, Marcy l’Etoile, France) allowed precise
and accurate identiﬁcation ofMucorales to the species level [53].
Alternative techniques such as matrix-assisted laser desorption/
ionization time-of-ﬂight (MALDI-TOF) mass spectrometry are
promising but not yet validated for all species.
Evidence—Although some genera, such as Cunninghamella,
may be associated with a higher mortality rate in patients
[3,5] and have been shown to be more virulent in exper-
imental models [54], there is currently sparse evidence that
identiﬁcation of the causative Mucorales to the genus and/or
species level could guide the choice of the antifungal
treatment [55,56].
In contrast, identiﬁcation to the species level is of interest
for better epidemiological knowledge of the disease. In
particular, the clinical picture may be different depending on
the species [3,5,57]. Moreover, species identiﬁcation could be
valuable for investigation of healthcare-associated mucormy-
cosis and outbreaks [58].
Identiﬁcation of Mucorales in culture by standard mycolog-
ical methods such as morphology is notoriously difﬁcult
because the different species share similar morphological
characteristics. This has been highlighted by recent molecular
description of cryptic species that can hardly be distinguished
morphologically [59–62]. Moreover, some species fail to
sporulate in standard media, precluding a timely and easy
morphological identiﬁcation [63]. A comparison of morpho-
logical versus molecular identiﬁcation of 19 isolates of
Mucorales from patients with mucormycosis showed that
identiﬁcation by morphology was erroneous in >20% of the
cases [64]. A high level of concordance (>90%) between
morphology and molecular identiﬁcation may be only seen in
reference laboratories [65].
Several DNA targets have been evaluated for a reliable
identiﬁcation to the species level. The best informative target
should have a large interspeciﬁc (between species) and a low
intraspeciﬁc (within a given species) sequence variability.
Moreover, a comprehensive and accurate database must be
available. In a study of 54 isolates from 16 different species it
has been shown that ITS sequencing was a reliable and
accurate method for identiﬁcation to the species level [66].
Similar results were obtained by other authors [67,68]. Based
on published results and expert opinions, the CLSI has
proposed ITS sequencing as a valuable method for identiﬁca-
tion of genus and also of species [69]. More recently, the
International Society for Human and Animal Mycology
(ISHAM) working group on fungal molecular identiﬁcation
has recommended using ITS sequencing as a ﬁrst-line method
for species identiﬁcation of Mucorales [70]. Other DNA
targets have also been evaluated including 18S, 28S, cyto-
chrome b or FTR1 [71–75] and could be used as alternatives
but for some of these targets there is less evidence of their
usefulness.
Alternative methods for rapid identiﬁcation of ﬁlamentous
fungi in clinical microbiology laboratories have been recently
evaluated. In particular, using ID32C strips or API 50 CH
carbon assimilation strips and 57 Mucorales strains, intraspe-
cies variation was found to be low, whereas large differences
were found between genera and species, allowing identiﬁcation
to the species level for all included strains except for Rhizopus
oryzae. The clustering of isolates based on their carbon
assimilation proﬁles was in accordance with DNA-based
phylogeny of Mucorales [53]. MALDI-TOF mass spectrometry
may be of interest although limited data are currently available
for Mucorales [76–78]. In an analysis of 103 ﬁlamentous fungi
by MALDI-TOF, the eight tested Mucorales were correctly
identiﬁed to species level [77]. In a more recent study it was
shown that 34 strains of Lichtheimia spp. could be reliably
identiﬁed by comparison to an in-house database constructed
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with 19 strains belonging to eight species [78]. Although
MALDI-TOF identiﬁcation of Mucorales seems promising,
more data are needed to validate this technique and
commercially available databases should be validated.
Recommendations—Identiﬁcation to the genus and species level
is strongly supported for a better epidemiological knowledge
of the disease. Guiding treatment by identifying to the genus
level is marginally supported. Carbon assimilation is moder-
ately supported and molecular identiﬁcation is strongly
supported in comparison to morphology. The best technique
for molecular identiﬁcation is ITS sequencing. There are
currently limited data for MALDI-TOF as an identiﬁcation
method. For further recommendations refer to Table 4.
Susceptibility testing. Evidence—European Committee on Anti-
microbial Susceptibility Testing (EUCAST) and CLSI (CLSI
M38-A2) [79,80] reference microdilution methods are used as
standard assays for antifungal susceptibility testing of Muco-
rales. Using methods other than the reference assays such as
Etest [21,55] or XTT assay [81,82] remains investigational.
Except for posaconazole, moderate (<80%) correlation of
Etest and Sensititre YeastOne with the CLSI M38-A2
method was noted in antifungal susceptibility testing of
Mucorales [21,79]. Rapid (within 6-8 h) susceptibility testing
can be achieved with the XTT assay [81]. Currently, there are
no validated MIC breakpoints for any of the drugs against
fungal genera in this order and so determination of suscep-
tibility categories (S, I and R) is not possible.
A correlation between the generated MIC and clinical
outcome was addressed in only a few studies. In a retrospec-
tive analysis of 16 patients infected with Apophysomyces elegans,
an amphotericin B MIC of <1 lg/mL correlated with recovery.
Of those infected with strains with an amphotericin B MIC of
≥1 lg/mL, 43% failed to respond [83]. Animal studies for
determination of in vitro–in vivo correlation are also limited. In
murine models of infections due to Rhizopus microsporus [84]
and Rhizopus oryzae [85] posaconazole was shown to be more
effective in infections due to strains with an MIC of 0.25 lg/mL
compared with those with an MIC of 2 lg/mL. On the other
hand, a low minimum fungicidal concentration, i.e. 0.5 lg/mL
of posaconazole was associated with response in mice infected
with Rhizopus oryzae. High posaconazole minimum fungicidal
concentration values, i.e. >16 lg/mL, correlated with clinical
failure in a similar murine model [82].
Antifungal susceptibility testing of the strains in the order
Mucorales has been performed mostly for epidemiological
purposes. The data presented in these studies provide
signiﬁcant clues for the expected susceptibility proﬁles and
are useful to evaluate genus-, species- and strain-based
variations in susceptibility. Fluconazole [84,86,87], voriconaz-
ole [84,86–91], echinocandins [84,87,90,91] and ﬂucytosine
[84,87,88,90,91] lack meaningful in vitro activity against Muco-
rales. In general, amphotericin B and posaconazole are the
most active drugs in vitro [84,86–92]. The comparative
activities of amphotericin B and posaconazole may vary
depending on the genus and species of the infecting strain.
Although amphotericin B yields lower MICs against Mucor
circinelloides compared with posaconazole [55,92], posaconaz-
ole MICs are lower than those of amphotericin B against
Cunninghamella bertholletiae [92,93]. On the other hand, high
MICs of both amphotericin B and posaconazole have been
reported for strains of Cunninghamella echinulata [93]. Spe-
cies-speciﬁc differences in azole and terbinaﬁne susceptibilities
are noted particularly for Rhizopus and Mucor [84,85,88,90].
Finally, strain-based variations have also been described, as for
TABLE 4. Recommendations on molecular based methods of identiﬁcation
Population Intention Method/Finding SoR QoE Comment References
Any To guide treatment Identiﬁcation to genus level C IIu Some species may be more virulent and/or associated
with higher mortality, e.g. Cunninghamella
3,5,54
Any To establish epidemiological
knowledge and for outbreak
investigation
Identiﬁcation to species level A IIu 3,5,25,65
Any To establish epidemiological
knowledge
Molecular identiﬁcation to
species level versus morphology
A IIu n = 19; ITS sequencing, concordance 79%, morphology
not reliable.
n = 190; ITS sequencing concordance 93%
64
65
Any To establish epidemiological
knowledge
Molecular identiﬁcation to
species level by ITS sequencing
A IIu Good discrimination of genera and species, ﬁrst-line
technique
66–70
Any To establish epidemiological
knowledge
Molecular identiﬁcation to species
level with other DNA targets
C IIu 28S PCR plus sequencing
18S PCR plus RFLP
28S MicroSeq kit
Cytochrome b gene real-time PCR
FTR1 gene sequencing
71
72
73
74
75
Any To establish epidemiological
knowledge
Carbon assimilation for species
identiﬁcation
B II ID32C and API 50 CH kits allowed precise and accurate
identiﬁcation
66
Any To establish epidemiological
knowledge
MALDI-TOF identiﬁcation C IIu Limited data, in house databases 77,78
ITS, internal transcribed spacer; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-ﬂight mass spectrometry; QoE, quality of evidence; RFLP, restriction fragment
length polymorphism; SoR, strength of recommendation.
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posaconazole susceptibility of Rhizopus oryzae strains [85,91].
Despite the lack of preference for its use in treatment of
mucormycosis, itraconazole MICs are relatively low for a
number of strains, including those of Rhizomucor [90,92] and
Lichtheimia [86,88,90,92].
Efﬁcacy of combination therapy was addressed in murine
models of mucormycosis. Improved survival was observed
with the combination of amphotericin B lipid complex and
caspofungin compared with monotherapy and untreated
controls in diabetic ketoacidotic mice infected with a more
virulent brain isolate of Rhizopus oryzae. However, improved
organ clearance was not achieved with combination therapy
[94]. In a murine model of disseminated mucormycosis caused
by Rhizopus oryzae, posaconazole combined with amphotericin
B at low dose (0.3 mg/kg/day) prolonged survival, and reduced
tissue burden was observed compared with monotherapy and
controls. However, it was not superior to amphotericin B
(0.8 mg/kg/day) alone [95].
In vitro combination studies have also been performed to
explore the interaction of antifungal agents against members of
the order Mucorales. The previously published reports include
data for combinations of amphotericin B and rifampin (69%
synergy, 31% indifference), amphotericin B and ﬂucytosine
(100% indifference), amphotericin B and terbinaﬁne (80%
indifference, 20% synergy), and terbinaﬁne and voriconazole
(56% indifference, 44% synergy) for miscellaneous genera of
Mucorales (n = 35) [96]. Data are also available for combina-
tions of amphotericin B and posaconazole: miscellaneous
genera (n = 21) with indifference in all strains [91]; Rhizopus
oryzae (n = 11), indifference in all strains [89]. The above
combination was more synergistic against hyphae than conidia
of miscellaneous genera (n = 30) [97]. Further data are
available for amphotericin B and anidulafungin (miscellaneous
genera, n = 21, indifference in 20 and synergy in one strain)
[91], for posaconazole and caspofungin (miscellaneous genera,
n = 12; synergy in all strains) [98], for posaconazole and
anidulafungin (miscellaneous genera, n = 21, indifference in all
strains) [91], and for itraconazole and terbinaﬁne (miscella-
neous genera, n = 17; synergy in 14 strains) [99].
Overall, and of major importance, the clinical signiﬁcance of
these and other in vitro and in vivo combination data remains
uncertain [100].
Recommendations—Given the relative lack of clinical break-
points and still limited sufﬁcient data to indicate a clear reading
correlation between MIC or minimum fungicidal concentration
values and clinical outcome, use of antifungal susceptibility
testing for guiding treatment in mucormycosis is recom-
mended only with marginal strength. Susceptibility testing for
attaining epidemiological data is strongly recommended. For
further recommendations refer to Table 5.
Imaging. There are obvious limitations for the differential
diagnosis between ﬁlamentous fungal infections if no histolog-
ical or cultural evidence is available. Some imaging character-
istics have been evaluated regarding their potential to
differentiate between fungal genera.
Evidence—The halo sign, i.e. a ring of ground glass opacity
surrounding a nodular inﬁltrate, and the air crescent sign, are
clinical criteria indicating lower respiratory tract fungal disease
[101], but they were not predictive of the genus of an invasive
fungal pathogen in a historical control study [102].
The reversed halo sign (also known as inversed halo sign or
atoll sign) is an area of ground glass opacity surrounded by a
ring of consolidation (Fig. 1). In an uncontrolled study on 189
patients treated for proven or probable invasive fungal
pneumonia the reversed halo was present in 19% of patients
TABLE 5. Recommendations on susceptibility testing in mucormycosis
Population Intention Method/Finding SoR QoE Comment References
Any To guide treatment EUCAST/CLSI reference
microdilution methods
C IIu Clinical relevance uncertain. No data available to
correlate MIC and outcome
79,80,83
Any To guide treatment Correlation of MIC with
in vivo outcome
C IIu For Apophysomyces elegans, limited retrospective
data suggest correlation
83
Any To guide treatment Correlation of MIC/MFC
with in vivo outcome
B III Animal, posaconazole better in Rhizopus microsporus
and Rhizopus oryzae strains MIC 0.25 lg/mL than
in those with MICs 2 lg/mL
82,84,85
Any To establish
epidemiological
knowledge
Susceptibility testing A IIu n = 37
n = 36
n = 217
n = 45
n = 77
n = 18, Apophysomyces elegans
n = 21
n = 66
Review
86
88
87
21
92
83
91
90
195
Any To establish
epidemiological
knowledge
MIC determined by
reference method
A III e.g. Etest not validated for Mucorales 79,80
MFC, minimum fungicidal concentration; QoE, quality of evidence; SoR, strength of recommendation.
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with mucormycosis, in <1% of patients with invasive aspergil-
losis, and in no patient with fusariosis. The majority of patients
with a reversed halo sign had undergone haematopoietic stem
cell transplantation for acute myelogenous or chronic
lymphatic leukaemia [103]. As a wide range of infectious and
non-infectious diseases may present with a reversed halo sign
on CT, the diagnostic value of this ﬁnding depends on the
pre-test probability [104].
Patients with more than ten nodular inﬁltrates were more
likely to have mucormycosis than aspergillosis in one historical
control study [102], whereas in a separate patient series this
was not the case [104].
If mucormycosis is the suspected diagnosis, histological
proof is urgently needed. Computed tomography-guided
needle biopsy was successfully applied in 61 patients with
possible invasive fungal diseases. Mucormycosis was diagnosed
in 13 (21%) [30]. In a separate series of 56 patients with
pulmonary nodular inﬁltrates on CT, biopsy identiﬁed proven
mucormycosis in six (11%) [47]. In both series a prerequisite
was a minimum platelet count of 50 000/lL, which can be
achieved by platelet transfusion [30].
Pleural effusion independently predicted mucormycosis in a
historical control study (n = 16) [102], and was found in all
patients of a second, independent series (n = 18) [104].
In a population of patients with haematological malignan-
cies (n = 59) about 20% of patients had disseminated
disease, so that cranial, thoracic and abdominal imaging
studies appear warranted [105]. In a historical control study,
31% of mucormycosis patients had sinus involvement [102].
In the 1980s, in two series (n = 10, each) of patients with
poorly controlled diabetes and mucormycosis cranial CT
revealed typical signs of sinusitis and orbital involvement
[106,107].
Sinusitis was more commonly associated with mucormyco-
sis than with invasive aspergillosis in patients with haemato-
logical disease [102]. Mucosal thickening without air/ﬂuid levels
was the usual ﬁnding in two series comprising ten patients each
[106,107].
In case of bone destruction diagnosed on CT, magnetic
resonance imaging should be used to reveal the full extent
of disease [108,109]. In an institutional series of patients
with mucormycosis (n = 27) approximately half of the
patients with sinus involvement showed intracranial spread
of disease [110].
Recommendations—In patients with haematological malignancy
it is recommended that the possibility of mucormycosis be
considered, particularly in the case of a lung inﬁltrate with a
reversed halo sign on CT. If mucormycosis is a potential
differential diagnosis, biopsy should be pursued. Once muco-
rmycosis has been proven in a patient with underlying
FIG. 1. Computed tomography in mucormycosis revealing a reversed
halo sign, also known as inversed halo or atoll sign.
TABLE 6. Recommendations on diagnosis of mucormycosis: imaging to differentiate between pulmonary mucormycosis and
invasive pulmonary aspergillosis
Population Intention Method/Finding SoR QoE References
Patients with haematological
malignancy
To differentiate mucormycosis from invasive
pulmonary aspergillosis
CT/reversed halo B IIu 103,104
Patients with haematological
malignancy
To differentiate mucormycosis from invasive
pulmonary aspergillosis
CT/pleural effusion C IIh 102,104
Patients with haematological
malignancy
To differentiate mucormycosis from invasive
pulmonary aspergillosis
CT/>10 nodular inﬁltrates C IIh 102,104
Patients with haematological
malignancy
To determine extent of disease CT cranial, sinus, thoracic,
abdominal
B III 105
Diabetic with facial pain,
sinusitis, proptosis, amaurosis
To diagnose invasive mould disease and to
determine extent of disease
Cranial CT/destruction
of bonea
A IIu 106–108
As above, but with bone
destruction on CT
To determine extent of disease (orbit,
cerebral, cavernous sinus thrombosis)
Cranial MRI A IIu 109,110
Asia, speciﬁcally China and India:
No underlying disease, ﬂank
pain, fever, haematuria, renal
infarct on Doppler ultrasound
To diagnose renal mucormycosis CT or MRI A IIu 9–11
Any To diagnose mucormycosis CT-guided biopsy A IIu 30,47
CT, computed tomography; MRI, magnetic resonance imaging; QoE, quality of evidence; SoR, strength of recommendation.
aSame approach for invasive aspergillosis.
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malignancy, cranial, thoracic and abdominal imaging studies are
recommended to determine the extent of disease. For further
recommendations refer to Table 6.
Recommendations on treatment of mucormycosis
Prophylaxis. Evidence—In two well-designed clinical trials eval-
uating primary antifungal prophylaxis during high-risk periods
of immunosuppressed patients, i.e. during long-lasting neutro-
penia in acute myelogenous leukaemia and during graft-ver-
sus-host disease with augmented immunosuppression, the
incidence rates of invasive fungal diseases were successfully
reduced by posaconazole 200 mg three times daily. Muco-
rmycosis only occurred in the comparator treatment arms of
the trials, i.e. ﬂuconazole or itraconazole, but the overall rate
was very low [111,112]. The prospective SEIFEM-B 2010
registry on newly diagnosed acute myelogenous leukaemia
(n = 515) compared posaconazole with itraconazole prophy-
laxis and no mucormycosis cases were diagnosed in either
group [113]. While ﬂuconazole [114] and voriconazole [115]
are not active against mucormycosis, itraconazole may yield
some activity, but may be inferior to posaconazole [116].
In immunosuppressed patients with a previous diagnosis of
mucormycosis (n = 3) surgery in combination with secondary
antifungal prophylaxis successfully prevented recurrence [117].
Another study reported a single case in support of this
approach [118].
Recommendations—During periods of graft-versus-host disease
with augmented immunosuppression and during outbreak
situations posaconazole primary prophylaxis is recommended
with marginal support for the speciﬁc prevention of muco-
rmycosis. We acknowledge that this is a rather artiﬁcial
scenario, since prophylaxis of invasive aspergillosis will be given
already. In patients with previous mucormycosis, surgical
resection and individualized secondary antifungal prophylaxis
are strongly supported. The last effective antifungal in the
respective individual should be preferred. For further recom-
mendations refer to Table 7.
Fever-driven treatment. Evidence—No clinical trial has been
conducted evaluating the timing of fever-driven treatment
directed against mucormycosis. In general, a diagnosis-driven
antifungal treatment is preferable [119].
Recommendations—If institutional epidemiology advocates mu-
cormycosis to be part of the antifungal spectrum, refer to
drugs and doses used for targeted treatment.
Targeted ﬁrst-line treatment. Evidence—In the ﬁeld of muco-
rmycosis no well-designed randomized clinical efﬁcacy trial has
been published. In a retrospective study on 30 patients
combined with a literature analysis of 225 patients with
mucormycosis, surgical debridement of lung involvement was
associated with a decrease of mortality from 62% to 11%.
Procedures were lobectomy, pneumonectomy or wedge
resection and patients with non-disseminated disease were
more likely to be treated surgically [120]. Two recent
literature reviews documented higher survival rates with a
combined modality approach of surgical and medical treatment
[3,121]. A large institutional series reinforced the need for a
combined therapeutic approach [38] and in posaconazole
salvage treatment of mucormycosis the highest cure rates
were achieved when surgery was part of the strategy [122]. A
multivariate analysis from an ECMM case registry [7] and a
retrospective analysis of a national case series also found
surgery associated with survival [25]. Surgery is of major
importance in rhino-orbito-cerebral locations, as evidenced in
a retrospective study, where the impact of local control on
survival was striking [123].
In an uncontrolled study in patients with haematological
malignancy the 12-week mortality rate increased two-fold with
medical treatment deferred for 6 or more days from onset of
symptoms [27].
Murine models suggest that liposomal amphotericin B is
more effective than the deoxycholate formulation against
mucormycosis [124], and that for liposomal amphotericin B
and amphotericin B lipid complex efﬁcacy was dose-dependent
[125]. Actually the lipid complex formulation reached higher
lung concentrations and better fungal tissue clearance than
liposomal amphotericin B [125]. Whereas both formulations
had similar efﬁcacy in neutropenic and diabetic ketoacidotic
mice, liposomal amphotericin B was more effective in reducing
TABLE 7. Recommendations on prophylaxis of mucormycosis
Population Intention Intervention SoR QoE Comment References
Neutropenic or GvHD
patients in an outbreak situation
To prevent Posaconazole 3 9 200 mg/day C III n = 1/602
n = 1/600
n = 0/353
111
112
113
Neutropenic or GvHD patients
in an outbreak situation
To prevent Fluconazole, itraconazole, voriconazole,
any dose
D II In vitro 114–116
Immunosuppressed, previous
diagnosis of mucormycosis
To prevent recurrence,
‘secondary prophylaxis’
Surgical resection and last drug effective in
the same patient, same dose as for treatment
A III n = 3
n = 1
117
118
GvHD, graft versus host disease; N/A, not applicable; QoE, quality of evidence; SoR, strength of recommendation.
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brain fungal burden [126]. In central nervous system disease
amphotericin deoxycholate and liposomal amphotericin
achieved the highest efﬁcacy in a rabbit model; however, this
model evaluated candidiasis [127].
In an uncontrolled retrospective study on patients with
haematological malignancy multivariate analysis revealed treat-
ment with liposomal amphotericin B 3 mg/kg/day to be
independently associated with cure [105]. An analysis from
the ECMM FungiScopeTM registry (www.fungiscope.net) dem-
onstrated that liposomal amphotericin B at an average dose of
5 mg/kg/day was associated with increased response and
survival rates [26]. The ECMM mucormycosis registry (www.
zygomyco.net) reported that a liposomal amphotericin B
median dose of 5 mg/kg/day (range 3–10 mg/kg/day) leads to
favourable response rates [7]. In invasive aspergillosis high-
dose liposomal amphotericin B (10 mg/kg/day) caused signif-
icantly more renal toxicity than the standard dose of 3 mg/kg/
day, but proved the general feasibility of high-dose regimens
[128]. A subsequent non-comparative clinical trial evaluated
the feasibility and efﬁcacy of liposomal amphotericin B 10 mg/
kg/day for the initial treatment of mucormycosis [129]. Renal
toxicity was frequent (40%), but treatment was feasible in
more than half of the patients; at week 12 the response rate
was 45% [57].
First-line treatment with amphotericin B lipid complex
5 mg/kg/day has been reported in a very limited number of
patients only [7,130]. In conjunction with the evidence from
animal models, central nervous system involvement should be
excluded if this formulation is to be used [126,127].
In immunocompetent mice amphotericin B prolonged
survival, whereas for itraconazole and posaconazole there
are heterogeneous effects depending on the fungal species
used for infection [131–133]. The ECMM clinical registries
reported successful ﬁrst-line treatment with posaconazole in
about 50–60% of patients [7,26]. Split doses of posaconazole
yield higher exposure, so that posaconazole 200 mg four times
daily is the preferred dosing regimen in mucormycosis
treatment [134].
Concomitant treatment with an amphotericin B formulation
and caspofungin has been described as successful in a limited
number of predominantly diabetic patients with rhinocerebral
mucormycosis [135].
Amphotericin B deoxycholate has been used as standard
treatment when no alternative was available [3]. When the
comparison to liposomal amphotericin B in fever-driven
treatment provided objective proof of its substantial toxicity,
the deoxycholate formulation was no longer appropriate,
although it is still used where resources are a constraint
[136,137]. Amphotericin B deoxycholate did not correlate
with superior recovery in a multivariate analysis in a haema-
tological malignancy population [105], in a large institutional
series with a variety of underlying diseases [38], and most
recently in an ECMM registry [7].
Recommendations—In patients with mucormycosis, surgery
whenever possible is strongly recommended to be combined
with medical treatment. Immediate treatment initiation is
strongly supported to increase survival rates. Liposomal
amphotericin B is the drug of choice and the dose should
be at least 5 mg/kg/day. The use of amphotericin B deoxy-
cholate is discouraged. For further recommendations refer to
Table 8.
Salvage treatment. Evidence—Salvage treatment may be neces-
sary because of refractoriness of disease, or because of
intolerance towards previous antifungal therapy, or because of
a combination of both.
In the posaconazole compassionate use programme,
investigators were allowed to switch between two oral
suspension dosing regimens, i.e. 200 mg four times daily and
400 mg twice daily. Rates of complete and partial response
[138] as well as survival approached 80% in patients with
refractory disease and in patients intolerant to previous
therapy [122]. A second analysis of a larger population from
the same programme described a treatment response rate
of 60% (overlap between both articles was 11 patients). An
additional 20% of patients achieved stable disease [139,140].
In the ECMM registry on mucormycosis patients the survival
rate of patients receiving posaconazole was 72% [7]. A
retrospective analysis of 96 published case reports of
posaconazole treatment found a 73% complete response
rate [141].
Other reports on salvage treatment cover series of smaller
patient numbers (n = 2 to n = 323). Liposomal amphotericin B
5 mg/kg/day has been used in patients intolerant to previous
amphotericin B deoxycholate treatment [105]. Amphotericin B
lipid complex 5 mg/kg/day was given in some patients with
refractory disease [130,142], in those intolerant to previous
therapy or with pre-existing renal disease [130]. In the latter
group, use of amphotericin B colloidal dispersion 5 mg/kg/day
was also reported [143].
The combination of lipid-based amphotericin B plus
caspofungin has been described in a few patients [135]. In
models of neutropenic and ketoacidotic mice the combina-
tion of liposomal amphotericin B and posaconazole did not
improve survival rates or reduce fungal tissue burden [144].
However, in a recent report on 32 patients with mainly
haematological diseases, combinations of lipid-based, mostly
liposomal, amphotericin B 3–5 mg/kg/day and posaconazole
800 mg/day were analysed [145]. Three months after
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initiation of treatment 56% had responded to treatment
[145].
Recommendations—For salvage treatment posaconazole
200 mg four times daily is strongly recommended, while
lipid-based formulations of amphotericin B and combination of
these two compounds are supported with moderate strength.
For further recommendations refer to Table 9.
Speciﬁc patient settings
Children. Mucormycosis is a life-threatening disease in immu-
nocompromised children and adolescents with haematological
malignancies, transplantation, immunosuppressive therapy,
diabetes, trauma or burns, and may also occur in premature
neonates. Whereas gastrointestinal and cutaneous disease is
the most common reported presentation in neonates, older
children and adolescents typically present with pulmonary,
rhino-orbito-cerebral, cutaneous, and disseminated disease.
Overall mortality is 64% in neonates and 42–56% in children.
Dissemination and age below one year are independent risk
factors for death in children. Similar to adults, surgery
combined with antifungal therapy is a factor associated with
survival [121,146–149]. Of note, in a large epidemiological
study from the USA, the incidence of mucormycosis was stable
over time and no relationship to the increasing use of
voriconazole among children was found [150].
Evidence—While the recommendations are similar to those
for adults, there are, however, subtle but important differ-
ences for paediatric patients. These differences are consistent
with paediatric development regulations and guidelines from
the European Medicines Agency (EMA) whose concepts have
been adopted by the 2012 ESCMID guideline for prevention
and management of invasive Candida infections in neonates
and children [151]. On the basis of this conceptual frame-
work, the group considered four components for grading of
therapeutic interventions: (i) evidence for efﬁcacy from adult
phase II trials and case series; (ii) existence and quality of
paediatric pharmacokinetic data and dosing recommenda-
tions; (iii) speciﬁc paediatric safety data and supportive
efﬁcacy data; and (iv) regulatory approval for use in paediatric
age group(s) [151].
Recommendations—Due to the absence of substantially different
and/or separate paediatric data, recommendations for diagnosis
(patient evaluation, diagnostic methods), principles of manage-
ment (antifungal therapy, control of the predisposing condition,
surgery), adjunctive treatments (granulocyte transfusions, cyto-
TABLE 8. Recommendations on targeted ﬁrst-line treatment of mucormycosis in adult patients
Population Intention Intervention SoR QoE Comment References
Any To increase survival rates Surgical debridement A IIu n = 32
n = 90
n = 45
n = 9
n = 59
n = 92, paediatric
120
3
38
7
25
121
Any To cure and to increase
survival rates
Surgical debridement in addition to antifungal
treatment
A IIu n = 470
n = 19
n = 90
n = 92, paediatric
3
122
7
121
Immunocompromised To increase survival rates Immediate treatment initiation A IIu n = 70 27
Any To cure and to increase
survival rates
Amphotericin B, liposomal ≥5 mg/kga A IIu n = 4
n = 16
n = 5
n = 21
n = 28
n = 130
n = 40
Animal model
Animal model
105
196
128
26
152
7
57
124
125
CNS To cure Amphotericin B, liposomal 10 mg/kg, initial 28 daysa A II Animal model
Animal model
127
126
Any, except CNS To cure Amphotericin B, lipid complex 5 mg/kga B IIu n = 10
n = 7
Animal model
Animal model
130
7
126
127
Any To cure Posaconazole 4 9 200 mg/day or 2 9 400 mg/daya B IIu n = 8
n = 17
Animal model
26
7
131
Any To cure Lipid-based amphotericin plus caspofungina C III n = 7 135
Any To cure Amphotericin B, deoxycholate, any dosea D I Renal toxicity
n = 9
n = 532
Renal toxicity
n = 10
n = 21
137
105
3
136
38
7
CNS, central nervous system; QoE, quality of evidence;.
aTreatment duration is determined on a case-by-case basis and depends, for example, on extent of surgery and organs involved.
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kines, hyperbaric oxygen, deferasirox), and timing/duration of
antifungal treatment of paediatric mucormycosis are similar to
those outlined for adults and are not recapitulated here.
Prompt initiation of treatment with amphotericin B and
consideration of surgery are critical for successful management
[121,146,148]. Based on observational data in adults
[7,26,130,142,152], paediatric pharmacokinetics [153–155],
safety data [148,154,156–159] and the existence of a paediatric
label, the choices for ﬁrst-line treatment in neonates, children
and adolescents include amphotericin B lipid complex and
liposomal amphotericin B. For pharmacokinetic and pharma-
codynamic reasons liposomal amphotericin B is the preferred
drug for infections involving the central nervous system [127].
While amphotericin B deoxycholate may have acceptable
safety and tolerability proﬁles in neonates [160], its use is
discouraged based on superior outcomes of lipid-amphotericin
B in animal models and adults [124,136]. Predominantly due to
the lack of clinical efﬁcacy data in adults in this setting,
posaconazole [7,26] and the combination of lipid-amphotericin
B plus caspofungin [135] are only recommended with marginal
strength for ﬁrst-line therapy of paediatric patients.
Indications for salvage therapy include refractory disease
and life-threatening toxicities of lipid amphotericin B; consid-
ering the high mortality of mucormycosis, pre-existing kidney
dysfunction is not a priori a contraindication for treatment
with lipid amphotericin B. Options for salvage therapy of
mucormycosis in children ≥2 years and adolescents include
posaconazole. This recommendation is based on adult efﬁcacy
data [122,139] and limited paediatric pharmacokinetic
[161,162] and safety data [161–164]. Although no data for
mucormycosis exist, demonstrating a trough serum concen-
tration of 0.7–1.0 lg/mL is reasonable to assume exposure on
the basis of treatment data obtained in patients with invasive
aspergillosis [165]. Further options for salvage therapy include
the combination of lipid amphotericin B plus caspofungin
[121,135,166–170], both compounds are approved for all age
groups, and the combination of lipid amphotericin B plus
posaconazole for children ≥2 years of age [95,144]. Of note,
posaconazole may also be used for consolidation treatment
and as secondary prophylaxis, respectively. For further
recommendations on ﬁrst-line treatment refer to Table 10,
and for salvage treatment refer to Table 11.
Haematological malignancy. Evidence—With the intent to cure
infection, granulocyte colony-stimulating factor has been
applied to shorten neutropenia as the key predisposing factor
for mucormycosis in this patient group. The results are difﬁcult
to interpret because of the small published patient numbers
(n = 5 to n = 18) [3,105,171–175]. Granulocyte transfusion
has been reported in an even more limited number of patients
(n = 7 to n = 8) to cure mucormycosis [3,105,175]. Granu-
locyte transfusion has been combined with recombinant
interferon-c 1b (n = 4) [176].
Recommendations—In patients with neutropenia, granulocyte
colony-stimulating factor is strongly recommended. The dose
should be chosen as licensed. For further recommendations
refer to Table 12.
Solid organ transplant recipients. Evidence—In solid organ trans-
plant recipients use of liposomal amphotericin B has been
reported to be associated with increased response rates
[25,177–179]. Speciﬁcally in pulmonary mucormycosis [177]
and in sino-nasal-cerebral disease surgery was associated with
TABLE 9. Recommendations on salvage treatment of mucormycosis in adult patients
Population Intention Intervention SoR QoE Comment References
Refractory to prior antifungal therapy To cure Posaconazole, oral suspension,
4 9 200 mg/day or 2 9 400 mg/daya
A IIu n = 19
n = 81b
n = 61
n = 15c
122
139
7
141
Intolerant to prior antifungal To cure Posaconazole, oral suspension,
4 9 200 mg/day or 2 9 400 mg/daya
A IIu n = 5
n = 43b
n = 15c
122
139
141
Intolerant to prior antifungal To cure Amphotericin B, liposomal, 5 mg/kg B IIu n = 8 105
Refractory to prior antifungal therapy To cure Amphotericin B, lipid complex, 5 mg/kg B IIu n = 16
n = 23
142
130
Intolerant to prior antifungal To cure Amphotericin B, lipid complex, 5 mg/kg B IIu n = 12 130
Intolerant due to pre-existing renal disease To cure Amphotericin B, lipid complex, 5 mg/kg B IIu n = 18 130
Intolerant due to pre-existing renal disease To cure Amphotericin B colloidal dispersion 5 mg/kg B IIu n = 21 143
Refractory disease or intolerant to prior
antifungal therapy
To cure Polyene plus caspofungin C III n = 2 135
Any To cure Polyene plus posaconazole B IIu n = 32 145
SoR, strength of recommendation; QoE, quality of evidence.
aTreatment duration is determined on a case-by-case basis and depends, for example, on extent of surgery and organs involved.
bThirty-three patients had both refractory disease and intolerance, 11 individuals are part of the Greenberg report, too.
cThe reason for salvage treatment, i.e. refractoriness versus intolerance, was not reported in this study.
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increased survival rates [179].
Recommendations—In solid organ transplant recipients surgery
and liposomal amphotericin B—usually in combination—are
strongly recommended. For further recommendations refer to
Table 13.
HIV infection and AIDS. Evidence—Mucormycosis may be found
in human immunodeﬁciency virus (HIV) -infected patients;
indeed, 2% of all mucormycosis patients in a large literature
review were infected with HIV. However, HIV and AIDS are
not considered risk factors speciﬁcally for mucormycosis [3].
Recommendations—Recommendations do not differ from other
populations described above. In HIV patients drug–drug
interactions of protease inhibitors and non-nucleoside reverse
transcriptase inhibitors would need to be considered.
Diabetes. Evidence—Control of hyperglycaemia and ketoaci-
dosis was suggested to be a beneﬁcial reversal of a risk factor
TABLE 10. Recommendations for mucormycosis in paediatric patients: ﬁrst-line
Population Intention Intervention SoR QoE Comment References
Paediatric To cure Amphotericin B and surgery A II Paed. 121,146,148
Paediatric beyond neonatal period To cure Amphotericin B, lipid complex 5 mg/kg/day A IIt Paed. PK
Paed. safety
Paed. safety
Adult
153
156
157
142
Paediatric beyond neonatal period To cure Amphotericin B, liposomal ≥5 mg/kg/day A IIt Paed. PK
Paed. safety
Paed, n = 20
Adult
Adult
Adult
155
159
148
26
152
7
Paediatric beyond neonatal period and
≥2 years old
To cure Posaconazole 4 9 200 or 2 9 400 mg/day;
<13 years old: body-weight-based ≤34 kg
18-24 mg/kg/day given in 4 divided doses.
C IIIt Paed. PK
Paed. safety
Paed, n = 5
Adult
n <17
Adult TDM
161,162,200
163
164
26
7
165
Paediatric patients beyond the neonatal
period
To cure Amphotericin B lipid-based plus caspofungin C IIIt n = 7, adult, 2nd line
Paed. PK
Paed. PK
Paed. safety
135
168
169
170
Neonates, in particular premature
neonates
To cure Amphotericin B, lipid complex 5 mg/kg/day A IIt Neo PK
Paed safety
Paed safety
Adult
Adult
154
156
157
142
130
To cure Amphotericin B, liposomal ≥5 mg/kg/day A IIt Neo safety
Paed safety
Paed, n = 20
Adult
Adult
Adult
158
159
148
26
152
7
To cure Amphotericin B, lipid-based plus caspofungin C IIIt Neo PK
Adult, second line
167
135
To cure Amphotericin B, deoxycholate 1–1.5 mg/kg/day D III Animal 124
CNS involved To cure Amphotericin B, liposomal 5–10 mg/kg/day A IIt Animal 127
CNS, central nervous system; Neo, neonates; Paed, paediatric; PK, pharmacokinetics; QoE, quality of evidence; SoR, strength of recommendation.
TABLE 11. Recommendations for mucormycosis in paediatric patients: salvage treatment
Population Intention Intervention SoR QoE Comment References
Paediatric beyond neonatal
period and ≥2 years old
To cure Posaconazole, 4 9 200 mg/day
or 2 9 400 mg/day; <13 years old:
body-weight-based
A IIt Paed. PK
Paed. PK
Paed. safety
Paed, n = 5
Adult
Adult
Adult TDM
161
162
163
164
122
139
165
Paediatric including neonates To cure Amphotericin B, lipid-based, plus
caspofungin
C IIIt Adult, n = 7
Animal
Neo PK cas, Paed PK cas
Paed PKcas
Safety cas
135
166
167
168
169
170
Paediatric beyond neonatal
period and ≥2 years old
To cure Amphotericin B, lipid-based, plus
posaconazole
C IIIt Animal
Animal
144
95
cas, caspofungin; Neo, neonates; Paed, paediatric; PK, pharmacokinetics; QoE, quality of evidence; SoR, strength of recommendation; TDM, therapeutic drug monitoring.
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for mucormycosis in a review of 145 patients (87 with
diabetes) [180], and in two institutional cohorts of 35 and 33
diabetic patients [38,181].
Surgery was associated with improved cure and survival
rates in a retrospective analysis of 101 patients with
mucormycosis, 23 of these were diabetic patients with a
64% rate of rhinocerebral involvement [25]. Institutional
cohorts of diabetic patients found surgery associated with
increased survival rates [38,181]. Across these studies
Rhizopus oryzae was the most frequently identiﬁed single
pathogen [25,38,180,181].
Recommendations—In uncontrolled diabetes mellitus the con-
trol of hyperglycaemia and ketoacidosis is strongly supported.
Surgery should be part of the therapeutic approach. For
further recommendations refer to Table 14.
Trauma patients. Evidence—Trauma is the third major group of
patients with mucormycosis [25]. Natural disaster and acci-
dents are the usual settings [2,182]. In trauma patients
mortality rates are lower than in patients with underlying
haematological malignancy or diabetes [3,25]. In addition,
trauma patients may be more likely to receive surgery and less
likely to develop disseminated disease. Although a shorter
duration of antifungal treatment may be feasible, a multimodal
approach of surgical debridement (until clear margins) and
antifungal treatment should improve response rates and has
therefore been advocated [2,7,67,182].
Recommendations—Surgical debridement and antifungal treat-
ment are strongly recommended in trauma patients with
mucormycosis (Table 15).
Adjunctive treatments and general management. Iron overload
may be a risk factor for mucormycosis [183,184], consequently
iron depletion through chelators could be a useful adjunctive
treatment.
Evidence—In murine models the iron chelator deferasirox
protected from mucormycosis [183] and enhanced the efﬁcacy
of liposomal amphotericin B [185]. Furthermore, deferasirox
was found to be safe in a phase II study in patients (n = 8) with
proven mucormycosis [186]. However, when deferasirox was
added to liposomal amphotericin B in a small (n = 20)
prospective, double blind, placebo-controlled trial in haema-
tological patients, the combination treatment group had a
higher mortality rate (82% versus 22%) at 90 days [187]. These
results are difﬁcult to interpret and may have been caused by
imbalanced baseline characteristics between the treatment
groups. In any case, it is difﬁcult to prescribe chelators in
haematological patients with mucormycosis, although it is
unclear whether other patient groups, e.g. diabetic patients
TABLE 12. Recommendations for mucormycosis in haematological malignancy
Population Intention Intervention SoR QoE Comment References
Haematological malignancy with ongoing neutropenia To cure infection GCSF, dose not reported A IIu n = 8
n = 12
n = 18
n = 18
n = 5
n = 8
171
175
105
3
174
173
Haematological malignancy with ongoing neutropenia To cure infection Granulocyte transfusion C IIu n = ?
n = 8
n = 7
105
175
3
Haematological malignancy with ongoing neutropenia To cure infection Granulocyte transfusion
plus interferon-c1b
C III n = 4 176
GCSF, granulocyte colony-stimulating factor; QoE, Quality of evidence; SoR, Strength of recommendation.
TABLE 13. Recommendations for mucormycosis in solid organ transplant recipients
Population Intention Intervention SoR QoE Comment References
Solid organ transplantation To cure AmB lipid
formulation
A IIh n = 25
n = 14, pulmonary
n = 3
178
177
25
Solid organ transplantation To cure Surgery A IIu n = 11, pulmonary
n = 10, sinu-nasal-cerebral
177
179
QoE, quality of evidence; SoR, strength of recommendation.
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with rhinocerebral mucormycosis, are suitable for such
treatment. This is one of the rare occasions when the group
had to vote on a recommendation (Table 16).
Lovastatin inhibits the in vitro growth of Rhizomucor pusillus
[188]. In a Drosophila model lovastatin had activity against
Mucor sp. and Rhizopus sp., and exhibited a synergistic effect
when combined with voriconazole, which species in the order
Mucorales are intrinsically resistant [189]. It is unknown
whether these observations are clinically meaningful.
Glucocorticosteroid treatment is a risk factor for fungal
infection and in patients with mucormycosis it should be
avoided. If this is not feasible then the dose should be reduced
to the minimum required [190].
Hyperbaric oxygen has been reported in small numbers of
patients in uncontrolled settings [3]. In a review of 28
published cases treated with adjunctive hyperbaric oxygen
mortality was only 6%. Besides small patient numbers, bias in
selecting patients suitable for the procedure, publication bias
and generally lower survival rates in haematological patients
limit the quality of evidence [107,191].
The optimal duration of treatment has not been studied
prospectively and is generally unknown. Duration of any of the
treatments above is based on individual decision.
Recommendations—In haematological patients with mucormy-
cosis, adjunctive treatment with deferasirox is discouraged,
whereas in other patient groups it is recommended with
marginal strength. It is strongly recommended to stop
glucocorticosteroid treatment in patients with mucormycosis.
We strongly recommend continuing antifungal treatment until
TABLE 14. Recommendations for mucormycosis in diabetic patients
Population Intention Intervention SoR QoE Comment References
Uncontrolled diabetes To cure Control of hyperglycaemia
and ketoacidosis
A IIu n = 87
n = 35
n = 33
Review
180
181
38
197
Uncontrolled diabetes with
rhinocerebral involvement
To cure and to
increase survival
Surgery A III n = 26
n = 14
n = 23
n = 14
181
38
25
123
Uncontrolled diabetes To cure GM-CSF 250–425 lg/day C III n = 3, adjunctive to medical
and surgical treatment
198
GM-CSF, granulocyte–macrophage colony-stimulating factor; QoE, quality of evidence; SoR, strength of recommendation.
TABLE 15. Recommendations for mucormycosis in trauma patients
Population Intention Intervention SoR QoE Comment References
Trauma To cure Surgical debridement
and antifungal treatment
A II n = 38
n = 5/129
n = 3/8
n = 44/929
n = 39/230
n = 13/13
n = 18/101
182
199
67
3
7
2
25
QoE, quality of evidence; SoR, strength of recommendation.
TABLE 16. Recommendations for adjunctive treatments and general management in mucormycosis
Population Intention Intervention SoR QoE Comment References
Haematological malignancy To cure Deferasirox 20 mg/kg/day, days 1–14 Da II n = 8
n = 20, increased mortality
186
187
Haematological malignancy To cure Exposure to 100% hyperbaric oxygen C IIIr n = 3 3,191
Other than haematological
malignancy
To cure Deferasirox, any dose C III No reference
found.
Other than haematological
malignancy
To cure Exposure to 100% hyperbaric oxygen C IIr n = 28, primarily patients with improvable
risk factors, i.e. diabetes, trauma
3,191
Glucocorticosteroid recipients To cure Stop, if feasible, if not: reduce dose of
glucocorticosteroids to minimum required
A IIr 190
Uncontrolled diabetes To cure Hyperbaric oxygen C IIu n = 5 107
Any To cure Lovastatin C III In vitro
animal model
188
189
Any To cure Continue treatment until complete response
(on imaging) and permanent reversal of
immunosuppression are achieved.
A III Optimal duration of treatment has not
been studied prospectively
No reference
found.
QoE, quality of evidence; SoR, strength of recommendation.
aVotes: C 4, D 9, abstain 3.
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complete resolution as demonstrated on imaging and perma-
nent reversal of risk factors is achieved. For further recom-
mendations refer to Table 16.
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